American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Trial in progress: Venetoclax in combination with ASTX727, an all-oral therapy for chronic myelomonocytic leukemia and other MDS/MPN with excess blasts (VICTORY MDS/MPN): A randomized, phase 2 trial
    Meeting Abstract

    Shallis, R. M.; Blaha, O.; Halene, S.; Mendez, L.; Podoltsev, N. A.; Caldwell, A.; Bewersdorf, J. P.; Little, R. F.; Piekarz, R.; Patnaik, M. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • High-dose targeted radiation with (131)I-apamistamab prior to HCT demonstrated a dose-response for durable complete remission in patients with R/R AML
    Meeting Abstract

    Litzow, M. R.; Chen, G.; Gyurkocza, B.; Nath, R.; Seropian, S.; Choe, H.; Abboud, C. N.; Koshy, N.; Tomlinson, B. K.; Abhyankar, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • High response rates following point-of-care anti-CD19 CAR T-cell therapy in adults with relapsed/refractory acute B lymphoblastic leukemia
    Meeting Abstract

    Fried, S.; Danylesko, I.; Marcus, R.; Itzhaki, O.; Yerushalmi, R.; Shem-Tov, N.; Sdayoor, I.; Shouval, R.; Jacoby, E.; Kedmi, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Longitudinal assessment of minimal residual disease (MRD) in the ATLAS randomized phase 3 trial of post-transplant treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide (R) alone in patients with newly diagnosed multiple myeloma (NDMM)
    Meeting Abstract

    Kubicki, T.; Dytfeld, D.; Wrobel, T.; Jamroziak, K.; Robak, P.; Czyz, J.; Tyczynska, A.; Druzd-Sitek, A.; Giannopoulos, K.; Nowicki, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Ibrutinib in combination with revlimid/dexamethasone (RD) in relapsed/refractory multiple myeloma (AFT-15)
    Meeting Abstract

    Efebera, Y.; Suman, V. J.; Dinner, S. N.; Rosko, A. E.; McKay, J. T.; Barth, P.; Hagen, P.; Usmani, S. Z.; Richardson, P. G.; Laubach, J. P.
    Blood (2023)

    Fulltext@MSK | Save
  • Updated results on a multicenter phase II study of a dose intensified pediatric regimen in adults with acute lymphoblastic leukemia: The 06-254 DFCI ALL consortium trial
    Meeting Abstract

    Valtis, Y. K.; Flamand, Y.; Shimony, S.; Place, A. E.; Silverman, L. B.; Vrooman, L. M.; Brunner, A. M.; Sallan, S. E.; Wadleigh, M.; Garcia, J. S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Bendamustine bridging versus standard of care chemotherapy on toxicity profile for multiple myeloma patients undergoing CAR T cell therapy
    Meeting Abstract

    Leyfman, Y.; Rajeeve, S.; Sheng, T.; Diniz, M.; Richard, S.; Jagannath, S.; Rossi, A. C.
    Blood (2023)

    Fulltext@MSK | Save
  • Risk factors of smoldering multiple myeloma: Results from the screened iStopMM study
    Meeting Abstract

    Thorsteinsdottir, S.; Sverrisdottir, I.; Rögnvaldsson, S.; Ekberg, S.; Hultcrantz, M.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B.; Sigurdardottir, M.; Thorsteinsdottir, I.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pre-treatment pulmonary assessment have limited utility in B-cell lymphoma patients treated with autologous anti-CD19 CAR T-cell therapy
    Meeting Abstract

    Sdayoor, I.; Shouval, R.; Fried, S.; Marcus, R.; Danylesko, I.; Yerushalmi, R.; Shem-Tov, N.; Itzhaki, O.; Jacoby, E.; Kedmi, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A global, phase 3, randomized, double-blind study to evaluate safety and efficacy of selinexor, an XPO-1 inhibitor, in combination with ruxolitinib in JAK inhibitor-naïve myelofibrosis (XPORT-MF-034)
    Meeting Abstract

    Maher, K.; Rampal, R. K.; Bose, P.; Podoltsev, N. A.; Harrison, C. N.; Hong, J.; Wang, X.; Chamoun, K.; Mascarenhas, J.
    Blood (2023)

    Fulltext@MSK | Save